Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin
Open Access
- 12 February 2003
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 46 (2) , 222-230
Abstract
This study examined the biological effects of the GIP receptor antagonist, (Pro3)GIP and the GLP-1 receptor antagonist, exendin(9–39)amide. Cyclic AMP production was assessed in Chinese hamster lung fibroblasts transfected with human GIP or GLP-1 receptors, respectively. In vitro insulin release studies were assessed in BRIN-BD11 cells while in vivo insulinotropic and glycaemic responses were measured in obese diabetic (ob/ob) mice. In GIP receptor-transfected fibroblasts, (Pro3)GIP or exendin(9–39)amide inhibited GIP-stimulated cyclic AMP production with maximal inhibition of 70.0±3.5% and 73.5±3.2% at 10−6 mol/l, respectively. In GLP-1 receptor-transfected fibroblasts, exendin(9–39)amide inhibited GLP-1-stimulated cyclic AMP production with maximal inhibition of 60±0.7% at 10−6 mol/l, whereas (Pro3)GIP had no effect. (Pro3)GIP specifically inhibited GIP-stimulated insulin release (86%; pp3)GIP, exendin(9–39)amide or a combination of both peptides (25 nmol/kg body weight, i.p.) to fasted (ob/ob) mice decreased the plasma insulin responses by 42%, 54% and 49%, respectively (ppob/ob) mice was decreased by 19%, 27% and 18% (pp3)GIP, exendin(9–39)amide or combined peptides but accompanying changes of plasma glucose were small. These data show that (Pro3)GIP is a specific GIP receptor antagonist. Furthermore, feeding studies in one commonly used animal model of obesity and diabetes, (ob/ob) mice, suggest that GIP is the major physiological component of the enteroinsular axis, contributing approximately 80% to incretin-induced insulin release.Keywords
This publication has 42 references indexed in Scilit:
- Characterization of the Cellular and Metabolic Effects of a Novel Enzyme-Resistant Antagonist of Glucose-Dependent Insulinotropic PolypeptideBiochemical and Biophysical Research Communications, 2002
- Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.Journal of Clinical Investigation, 1998
- Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.Journal of Clinical Investigation, 1996
- Investigation of Glucose-dependent Insulinotropic Polypeptide(1-42) and Glucagon-like Peptide-1-(7-36) Degradation by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass SpectrometryJournal of Biological Chemistry, 1996
- Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.Journal of Clinical Investigation, 1996
- Glucagon-like peptide-1 is a physiological incretin in rat.Journal of Clinical Investigation, 1995
- Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patternsJournal of Endocrinology, 1993
- Comparison of the effect of GIP and GLP‐1 (7–36amide) on insulin release from rat pancreatic isletsEuropean Journal of Clinical Investigation, 1992
- Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acidsInternational Journal of Peptide and Protein Research, 1990
- Determination of glucose by an automatic analyserClinica Chimica Acta, 1971